The small molecule RS-1 was developed as an allosteric effector to exploit overexpression of RAD51 activity by further stimulating the formation of toxic RAD51 complexes on undamaged chromatin as a potential cancer therapy (160, 161). This evidence concerns the gene RAD51 and cancer.